Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study

Authors

Arthur Bobin,[1] Salomon Manier.[2] Joe de Keizer,[3] Jaydeep K. Srimani,[4] Cyrille Hulin,[5] Lionel Karlin,[6] Denis Caillot,[7] Ingrid Lafon,[7] Clara Mariette,[8] Carla Araujo,[9] Bertrand Arnulf,[10] Benoît Bareau,[11] Karim Belhadj,[12] Lofti Benboubker,[13] Thorsten Braun,[14] Claire Calmettes,[15] Olivier Decaux,[16] Mamoun Dib,[17] Hélène Demarquette,[18] Caroline Jacquet,[19] Cécile Sonntag,[20] Sophie Godet,[21] Arnaud Jaccard,[22] Pascal Lenain,[23] Margaret Macro,[24] Valentine Richez-Olivier,[25] Mourad Tiab,[26] Laure Vincent,[27] Hacene Zerazhi,[28] Marie-Odile Pétillon,[29] Sandrine Rollet,[29] Helene Gardeney,[1] Geraldine Durand,[1] Anthony Levy,[30] Cyrille Touzeau,[31] Aurore Perrot,[32] Philippe Moreau,[31] Thierry Facon,[2] Jill Corre,[33] Stephanie Ragot,[3] Herve Avet-Loiseau[33] and Xavier Leleu[1]

[1]Poitiers University, U1313, U1402, Poitiers, France; [2]Department of Hematology, University Hospital and INSERM UMR-S1277, Lille, France; [3]Clinical Investigation Center CIC INSERM 1402, University Hospital, Poitiers, France; [4]Takeda Development Center Americas, Cambridge MA, USA; [5]Department of Hematology, Haut-Lévêque Hospital, Pessac, France; [6]Department of Clinical Hematology, Civils Hospices, Lyon, France; [7]Department of Oncology Hematology, Bourgogne Cancerology Institute, Dijon, France; [8]Department of Hematology, University Hospital, Grenoble, France; [9]Department of Hematology, Côte Basque Hospital, Bayonne, France; [10]Department of Hematology, Saint-Louis Hospital, Paris, France; [11]Department of Hematology, Private Hospital, Cesson-Sévigné, France; [12]Lymphoid Hemopathies Unit, Henri Mondor University Hospital, Créteil, France; [13]Department of Hematology and Cell Therapy, Tours University Hospital, France; [14]Department of Clinical Hematology, Avicenne Hospital, Bobigny, France; [15]Department of Onco-Hematology, Périgueux Hospital, Périgueux, France; [16]Department of Clinical Hematology, UMR U1236 INSERM, Rennes University, Rennes, France; [17]Blood Disease Department, University Hospital, Angers, France; [18]Department of Hematology, Dunkerque Hospital, Dunkerque, France; [19]Department of Hematology, University Hospital - Brabois Hospitals, Vandoeuvre les Nancy, France; [20]Department of Hematology, ICANS University Hospital, Strasbourg, France; [21]Department of Clinical Hematology, University Hospital, Robert Debré Hospital, Reims, France; [22]Department of Clinical Hematology and Cell Therapy, University Hospital, Limoges, France; [23]Department of Hematology, Henri Becquerel Center, Rouen, France; [24]Department of Cinical Hematology, University Hospital, Caen, France; [25]Department of Clinical Hematology, Archet Hospital, Nice, France; [26]Department of Onco-Hematology, Vendée Departmental Hospital, La Roche/Yon, France; [27]Department of Clinical Hematology, Montpellier University, Montpellier, France; [28]Department of Onco-Hematology, Henri Duffaut Hospital, Avignon, France; [29]Intergroupe Francophone du Myélome, Paris, France; [30]Department of Onco-Hematology, Vichy Hospital, Vichy, France; [31]Department of Clinical Hematology, University Hospital, Hôtel Dieu, Nantes, France; [32]Department of Hematology, CRCT INSERM 1037, University Hospital, IUCT-O, Toulouse, France and [33]Unit for Genomics in Myeloma, CRCT INSERM 1037, University Hospital, IUCT-O, Toulouse, France

Correspondence:
X. LELEU - xavier.leleu@chu-poitiers.fr

https://doi.org/10.3324/haematol.2024.285916

Received: June 14, 2024.
Accepted: November 5, 2024.
Early view: November 14, 2024.

Ixazomib, Pomalidomide and dexamethasone in Relapsed or refractory Multiple Myeloma characterized with High-risk cytogenetics. IFM 2014-01.

Supplemental materials.

Supp Table 1. Patients' median survival time-to-event after a median follow-up time of 27 months, and response rates, as a whole and according to their abnormalities t(4;14) and Del(17p), at inclusion.

	All (n=26)	t(4;14) (n=9)	Del(17p) (n=12)	Del(17p) and t(4;14) (n=5)
Progression, n	22	7	11	4
Death, n	15	3	7	5
Months (95%CI)				
TTP	10.2 (4.4;13.0)	10.5 (7.9;NE)	9.9 (3.3;NE)	5.5 (2.7;NE)
PFS	8.9 (4.2;12.7)	10.2 (4.4; NE)	7.03 (2.3; NE)	5.5 (2.7; NE)
OS	23.7 (12.2; NE)	NE (27.1; NE)	23.7 (14.3; NE)	11.1 (9.9; NE)
Response rates at end of study, n (%)				
ORR	15 (60)	5 (62)	7 (58)	3 (60)
≥ VGPR	7 (28)	3 (38)	1 (8)	3 (60)
CBR	18 (72)	7 (88)	8 (67)	3 (60)

ORR. Overall response rate; VGPR. Very good partial response; CBR. Clinical beneficial rate; responses per IMWG criteria [11]. NE. not estimable. TTP. Time to progression. PFS. Progression free survival. OS. Overall survival. n. numbers
Kaplan-Meier method was used to analyze time-to-event data. Results were expressed as median time-to-event in months and 95% confidence interval (95%CI).

Supp Table 2. Summary of adverse events of grade 3 or higher according to MedDRA Hierarchy preferred term, as a whole and according to their abnormalities, t(4;14) and Del(17p), at inclusion, n (%).

	All (n=26)	t(4;14) (n=9)	Del(17p) (n=12)	Del(17p) and t(4;14) (n=5)
Neutropenia	52 (68)	34 (76)	4 (40)	14 (64)
Neoplasms benign, malignant and unspecified	4 (5)	0 (0)	2 (20)	2 (9)
Dyspnea	3 (4)	1 (2)	0 (0)	2 (9)
Infection	3 (4)	3 (7)	0 (0)	0 (0)
General physical health deterioration	3 (4)	2 (4)	1 (10)	0 (0)
Rash	3 (4)	0 (0)	1 (10)	2 (9)
Peripheral sensory neuropathy	2 (3)	2 (4)	0 (0)	0 (0)
Muscle spasms	2 (3)	1 (2)	1 (10)	0 (0)
Diarrhea	2 (3)	1 (2)	0 (0)	1 (5)
Renal and urinary disorder	1 (1)	0 (0)	0 (0)	1 (5)
Cardiac disorder	1 (1)	0 (0)	1 (10)	0 (0)
Psychiatric disorder	1 (1)	1 (2)	0 (0)	0 (0)

Supp Figure 1. CONSORT Patient Flow Diagram. (n=26)



n: number; AE/SAE: adverse event, serious adverse event; ANSM: medical agency France; #number per protocol